(NASDAQ: CAI) Caris Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.34%.
Caris Life Sciences's revenue in 2025 is N/A.On average, 10 Wall Street analysts forecast CAI's revenue for 2025 to be $206,683,906,974, with the lowest CAI revenue forecast at $199,635,876,838, and the highest CAI revenue forecast at $216,858,125,018. On average, 10 Wall Street analysts forecast CAI's revenue for 2026 to be $280,671,294,593, with the lowest CAI revenue forecast at $257,758,142,976, and the highest CAI revenue forecast at $301,897,207,610.
In 2027, CAI is forecast to generate $342,526,364,522 in revenue, with the lowest revenue forecast at $311,208,056,069 and the highest revenue forecast at $367,637,440,669.